The Retreatment of Genotype 4 Chronic Hepatitis C Patients with Pegylated Interferon Alpha-2a and Ribavirin

Peedikayil, Musthafa; Ashgar, Hamad Al; Kahtani, Khalid Al; Sohaibani, Fahad Al; Ingvar, Kagevi; Quaiz, Mohammed Al

doi:10.14309/00000434-201310001-00451

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies with a total of 126 individuals were included in our pooled analysis ( figure 1 ). Two studies originated from Saudi Arabia 12 13 and another from Portugal. 14 All three studies were retrospective in design.…”

Section: Resultsmentioning

confidence: 99%

“… 14 All three studies were retrospective in design. One study 13 provided analysis based on ITT, with 37 of 56 (66%) patients actually completing treatment. Of the other two studies, 51 of 59 patients (86.4%) completed treatment in one, 12 while the other 14 did not disclose the rate of treatment completion.…”

Section: Resultsmentioning

confidence: 99%

“…One study 13 noted that SVR was higher in patients who experienced previous treatment failure due to relapse (50%) versus the non-responders (23.1%).…”

Section: Resultsmentioning

confidence: 99%

“…Only one of these studies reported baseline characteristics for the targeted patient population, preventing in-depth analysis of possible prognostic factors for SVR. 12 The pooled estimate for the rate of re-treatment success with P/R between prior relapsers versus non-responders, which may vary significantly, 13 could not be determined due to lack of primary data. Study patients were also heterogeneous with regard to types of IFN or use of RBV during prior therapies; nevertheless, pooled SVR was low even with inclusion of patients who may have had only standard IFN and without RBV.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis

Zhang

Nguyen

Yee

et al. 2015

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundAn estimated 170 million people worldwide are infected with hepatitis C virus (HCV). HCV genotype 4 (HCV-4)—the most prevalent hepatitis C strain in the Middle East and Africa—is difficult to treat, with an estimated sustained virological response (SVR) of 53% when using pegylated interferon and ribavirin (P/R) in treatment-naïve patients with HCV-4 infection. In regions where access to direct-acting antivirals is limited, re-treatment of patients who failed therapy with another course of P/R may be an option if the success rate is acceptable.ObjectivesWe aimed to determine the SVR from retreatment with P/R in treatment-experienced patients with HCV-4 infection.MethodsWe performed a meta-analysis using MEDLINE and EMBASE searches, and by reviewing article bibliographies and abstracts from recent Liver Society Meetings. Original studies featuring at least 10 adult, treatment-experienced patients with HCV-4 infection failing prior interferon-based therapy and receiving subsequent re-treatment with P/R were included.Results3 studies were included. Overall pooled SVR was 32.7%, or 41/126 patients. No significant heterogeneity existed among the studies. One study reported higher SVR of 50% in previous relapsers, compared with 23% in previous non-responders.ConclusionsAs expected, treatment-experienced patients achieved lower rate of SVR compared with previously reported SVR for treatment-naïve patients with HCV-4 infection. The abysmal rate of success from re-treatment with P/R supports the use of direct-acting antivirals whenever re-treatment is considered, even in resource-limited regions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…One study 13 noted that SVR was higher in patients who experienced previous treatment failure due to relapse (50%) versus the non-responders (23.1%).…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations